Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41 results about "Colonic Carcinoma" patented technology

Composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases

The invention belongs to the technical field of formulas of medicament for preventing and treating physical diseases and particularly relates to composition capable of preventing and treating respiratory system diseases like novel coronavirus infection and other diseases. Alliin, alliinase and type II transmembrane serine protease inhibitor are taken as basic effective ingredients, the compositionis administered in a way of inhalation by the lung, can kill physical diseases caused by bacteria such as methicillin-resistant staphylococcus aureus, multidrug resistance type escherichia coli, multidrug resistance type pseudomonas aeruginosa, multidrug resistance type mycobacterium tuberculosis and the like, viruses such as SARS-CoV-2 and the like, fungi such as multidrug resistance type candida albicans and the like, parasites and the like in a respiratory system and also can prevent fat accumulation in blood vessels of a human body, reduce the blood pressure, the cholesterol level in blood and destroy cancer cells of multiple epithelial tumors of breast cancer, ovarian cancer, colon cancer, renal carcinoma, liver cancer, lung cancer, mesothelioma and prostatic cancer, and the composition has no any toxic or harmful functions and risks and has broad application prospects.
Owner:WUXI HONGRUI BIOMEDICAL TECH CO LTD

Application of compound in tumor resistance

The invention relates to the technical field of medicines, in particular to application of a compound with a structure shown in a formula (I) (shown in the description) in preparation of a medicine for preventing or treating malignant tumor associated with cyclin-dependent kinase 2 (CDK2). Based on researches, the compound and pharmaceutically acceptable salt thereof have excellent inhibitory activity to the CDK2, remarkably inhibit the growth activity of a human colonic cancer cell HCT-116, a human breast cancer cell MCF-7, a human lung cancer cell A549 and a human liver cancer cell SMMC-7721, can block the cell cycle of cancer cells and facilitate apoptosis of the cancer cells; the compound and the pharmaceutically acceptable salt thereof can be applied to treatment of various malignant tumors.
Owner:WUHU YANGYAN PHARMA

Oral medicine for colorectal carcinoma fistulation later-stage nursing, and its preparation method

The invention discloses an oral medicine for colorectal carcinoma fistulation later-stage nursing, and its preparation method. The medicine comprises 50-80 parts of Semen Phaseoli, 35-70 parts of Holothuria leucospilota, 40-90 parts of Meliosma fordii, 30-60 parts of roxburgh rose root, 24-60 parts of baccate sedge herb, 32-56 parts of shrubalthea root, 18-30 parts of radix paeoniae rubra, 22-46 parts of Inonotus cuticularis (Bull.: Fr.) Karst., 18-34 parts of konjac, 8-20 parts of Ajuga pantantha, 20-38 parts of Coriolus versicolor(L.ex Fr.)Quel., 20-50 parts of Cinnamomum wilsonii Gamble and 45-86 parts of Begonia yunnanensis Levl.. The medicine has strict composition and reasonable compatibility, has the efficacies of heat clearing, blood activating, diuresis inducing, channel freeing, intestine widening, qi rectifying, intestine damp heat removing, intestine moistening, bowel relaxing, blood circulation invigorating, bleeding stopping, qi moving, pain relieving, and stomach and intestine distention qi mitigating, comprises Chinese herbal medicines benefiting the rehabilitation of alimentary canal tumors and adjusting the immune function, can condition colorectal carcinoma patients subjected to fistulation, and has a good nursing efficacy on later-stage fistulization stoma complications.
Owner:张焕秀

Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis

The present invention is based on the key roles played by Hedgehog proteins in the regulation of homeostasis of the adult intestinal epithelium. Ihh is expressed in the adult mammalian colon and provides a lineage-instructive signal and regulates colonic epithelial morphogenesis in a compartmental fashion. Loss of Ihh expression precedes morphological change in colon tumorigenesis, i.e. carcinogenesis, and Ihh was absent in HT-29 colon carcinoma cells. Treatment of cancerous HT-29 cells with exogenous Hedgehog protein restored their differentiation. Ihh thus plays a pivotal role in the maintenance of colonic epithelial homeostasis in the differentiation of the GI tract cells and is essential for the enrolment of these GI tract cells on the Death program thus maintaining homeostasis to avoid or treat carcinogenesis. In addition, in gastric cancer expression of Shh is lost and loss of Shh expression precedes morphological changes in the parietal cells of the stomach. Shh is specifically expressed in fundic glands as well as in gastric heterotopia in the esophagus in Meckel's diverticulum. Shh thus has a unique role as a morphogen in fundic gland homeostasis. The present invention relates to methods in which a source of Hedgehog proteins is used prophylactically or therapeutically to maintain homeostasis of the adult intestinal epithelium. In particular the invention relates methods whereby sources of Hedgehog protein are used to prevent or treat carcinogenesis in adult gastric and colonic tissues. The invention also relates to Hedgehog-based method of diagnosing susceptibility for or the presence of carcinogenesis in the adult GI tract, particularly in gastric and colonic tissues. The invention further provide for compositions to be used in the Hedgehog-based methods of diagnosing, preventing and treating epithelial tumorigenesis in the adult GI tract.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT

Novel pyrido sulfur nitrogen 7-membered ring derivatives adopted as anti-tumor drugs, preparation method and applications thereof

The invention relates to multi-substituted pyrido sulfur nitrogen 7-membered ring derivatives represented by a general formula I-1, wherein the derivatives have wide anti-tumor activities. In vitro cell test results show that the compounds provide good inhibition effects for multiple human tumor cell lines, wherein the human tumor cell lines comprise human leukemia cell line OP-1, human colon carcinoma cell line HT29, human lung cancer cell line H460, paclitaxel resistant human lung cancer cell line H460TaxR, adriamycin resistant human breast cancer cell line MCF-7 / Adr and the like. According to the present invention, pharmaceutical auxiliary materials can be mixed with the compounds of the present invention independently or mixtures of the compounds and effective components of other anti-tumor drugs to prepare pharmaceutical formulations for treatments of various tumor diseases. The compounds represented by the I-1 are prepared by carrying out condensation and oxidation on compounds represented by a formula I-2 and R7COZ (Z is OH or halogen).
Owner:CHANGCHUN DISCOVERY SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products